Topic: Life sciences and healthcare

As recent innovations in Artificial Intelligence (“AI”) such as ChatGPT ignite debate over issues such as the legal status of non-humans, privacy implications of novel computing abilities, and rights of intelligent systems’ creators over output, similar considerations confront another emerging computing field—one involving human cells.

The European Commission (along with the US FTC and DOJ, UK CMA, German FCO and others), has been focused on ensuring that so-called “killer acquisitions” in the digital and life sciences sectors are reviewed. Against this background, the General Court’s decision in Illumina/Grail is of key importance to companies acquiring start-ups.

As the telemedicine industry continues to grow, especially in light of COVID-19, businesses should reconsider their policies and procedures in connection with telehealth services and user safety.